Periodic Reporting for period 4 - RespiriTB (Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors)

Mycobacterium tuberculosis (Mtb) causes over 1.5 million deaths each year and has recently reclaimed the position of number one infectious disease killer worldwide. The currently recommended treatment regimens are composed of multiple drugs that need to be taken for a minimum...